מכפיל P/S עתידי: Alexandria Real Estate Equities (ARE)
Alexandria creates unique ecosystems for the development of biotech startups. The future multiplicative P/S valuation helps track the market value of these innovations, where the value of 2.80 represents the current metric. Alexandria owns elite laboratory clusters in the largest hubs, utilizing complex engineering standards. Long-term contracts with global pharmaceutical leaders ensure the stability of the business.
פילוחים אנליטיים של חברת Alexandria
The specificity of Alexandria (ARE) lies in managing specialized biotech real estate with minimal operating expenses by passing costs onto tenants. The forward P/S reflects the ratio of market capitalization to expected sales volume, allowing for an assessment of the value of each unit of projected revenue. This forward price-to-sales multiple chart helps investors recognize asset overvaluation in a timely manner and avoid buying at the peak of the trend.
